Introduction {#ics12532-sec-0009}
============

The skin\'s uppermost layer, the stratum corneum (SC), has been described as a brick‐and‐mortar organization thereby providing a barrier function against dehydration and environmental impacts. In this analogy, corneocytes represent the 'bricks' which are embedded in intercellular lipid layers, the 'mortar', and hence, the mechanical strength of corneocytes is a key element in the skin barrier integrity and functions [1](#ics12532-bib-0001){ref-type="ref"}. Corneocytes remain in their former keratinocyte architecture with the aggregation of keratin and the consistent crosslinking of structural proteins in the internal part of the cell membrane to create the insoluble corneocyte protein envelope [2](#ics12532-bib-0002){ref-type="ref"}. Meanwhile, phospholipases degrade cell membrane phospholipids of keratinocytes and lamellar bodies to generate free fatty acids supporting the acidification of the SC [3](#ics12532-bib-0003){ref-type="ref"}. The covalent attachment of *ω*‐hydroxyceramides to the corneocyte envelopes (CE) external surface form the corneocyte lipid envelope (CLE) then proceeds first through a peroxidation reaction through the action of 12R‐lipoxygenase (12R‐LOX) [4](#ics12532-bib-0004){ref-type="ref"}, [5](#ics12532-bib-0005){ref-type="ref"}. The crosslinking of proteins and the attachment of lipids are mediated then by transglutaminases (TGs) [6](#ics12532-bib-0006){ref-type="ref"}. These two processes contribute to the gain in rigidity and hydrophobicity of CEs defining their maturity [7](#ics12532-bib-0007){ref-type="ref"}, [8](#ics12532-bib-0008){ref-type="ref"}, [9](#ics12532-bib-0009){ref-type="ref"}, [10](#ics12532-bib-0010){ref-type="ref"}. The maturity of corneocytes contribute to the integrity [11](#ics12532-bib-0011){ref-type="ref"} and cohesion [12](#ics12532-bib-0012){ref-type="ref"} of the SC in order to support its function [13](#ics12532-bib-0013){ref-type="ref"}. The presence of mature CEs and the intercellular lamellar lipids contributes to a healthy skin barrier functioning [2](#ics12532-bib-0002){ref-type="ref"}. The *ω*‐hydroxyceramides result from the catalytic action of 12R‐LOX on esterified *ω*‐hydroxyacyl‐ceramides (CER EOS) at its linoleic acid domain which gets further processed by other enzymes such as epidermal LOX‐3 (eLOX3) and other hydrolases [14](#ics12532-bib-0014){ref-type="ref"}, [15](#ics12532-bib-0015){ref-type="ref"}, [16](#ics12532-bib-0016){ref-type="ref"}, [17](#ics12532-bib-0017){ref-type="ref"}, [18](#ics12532-bib-0018){ref-type="ref"}. Mutations in 12R‐LOX have been associated with autosomal recessive congenital ichthyosis in humans [19](#ics12532-bib-0019){ref-type="ref"}. A knock‐out model has shown that homozygous mutant mice lack a skin barrier to an extent that post‐natal death occurred within 5 h because of severe dehydration [5](#ics12532-bib-0005){ref-type="ref"}. Also, the CLE has been proposed to originate from lamellar‐body limiting membranes [20](#ics12532-bib-0020){ref-type="ref"}. More recently, mass spectrometry has revealed low 12R‐LOX protein levels in photodamaged facial SC [21](#ics12532-bib-0021){ref-type="ref"} which is associated with a thinner SC and reduced CE maturation [9](#ics12532-bib-0009){ref-type="ref"}. It is likely that facial SC has reduced acyl‐ceramide linoleate levels that contribute to this reduced CE maturation [22](#ics12532-bib-0022){ref-type="ref"}, [23](#ics12532-bib-0023){ref-type="ref"}, and age‐related reductions in covalently bound ceramides have been reported [24](#ics12532-bib-0024){ref-type="ref"}. However, the activity of 12R‐LOX has not been determined in these conditions.

Our aim was the establishment of a novel enzyme assay for 12R‐LOX in order to understand its relationship with facial photodamage. Little is known about the levels of 12R‐LOX in facial SC except the study of Voegeli *et al*. [21](#ics12532-bib-0021){ref-type="ref"}, and there is no detail on its activity as there are no specific inhibitors, and only a few antibodies have been described. Nevertheless, using ethyl linoleate as the substrate we were able to demonstrate specificity utilizing a 12R‐LOX antibody and showed changes in 12R‐LOX activity in tape strippings of photodamaged and non‐photodamaged facial skin for the first time.

Materials and methods {#ics12532-sec-0010}
=====================

Study design {#ics12532-sec-0011}
------------

Ethical approval for this study was received by UCL\'s Research Committee and the NHS London‐Bromley Research Committee (Reference: 16/LO/1672). Twelve healthy Chinese subjects (six females and males each, 26 ± 3 years old, median age 25 years) were recruited and signed the written informed consent before the study. The participants were not allowed to apply any cosmetic product on the face for at least 15 days prior to SC sampling.

SC sampling {#ics12532-sec-0012}
-----------

Nine consecutive standard D‐Squame^®^ tapes (diameter: 2.2 cm, area: 3.8 cm^2^) (CuDerm Corporation, Dallas, TX, U.S.A.) were taken from the photo‐exposed (PE) cheek (3 cm under the outer edge of the eye) and the photo‐protected (PP) post‐auricular sites (behind the earlobe). Tape strippings were performed on acclimatized skin for 20 min (19 ± 2°C; 44 ± 7% RH) using a pressure device (CuDerm Cooperation) applying 225 g cm^−2^ pressure on the tape for 5 s with intervals of 20 ± 5 s between each tape stripping which were removed in a single movement [25](#ics12532-bib-0025){ref-type="ref"}. SC protein content was measured via infrared densitometry using a SquameScan™850A (Heiland Electronics GmbH, Wetzlar, Germany) [26](#ics12532-bib-0026){ref-type="ref"}. Transepidermal water loss (TEWL) was measured at baseline and 30 ± 5 s after the third, sixth and ninth tape strippings to ensure consistent SC integrity (Aquaflux AF102; Biox Systems Ltd, London, U.K.). The first and ninth tapes were used to analyse the relative CE maturity (RCEM) [9](#ics12532-bib-0009){ref-type="ref"} while the second and eighth tapes were allocated for the 12R‐LOX enzyme assay.

Immunostaining {#ics12532-sec-0013}
--------------

Corneocyte envelopes were isolated with 750 *μ*L dissociation buffer containing 20 mmol L^−1^ Tris‐HCl pH 8.0, 5 mmol L^−1^ EDTA, 2% SDS, and 10 mmol L^−1^ [dl]{.smallcaps}‐dithiothreitol for 15 min at 75°C, shaking at 600 rpm (Eppendorf, Stevenage, U.K.). CE pellets were obtained by centrifugation at 5000 *g* for 10 min and suspended in 50 *μ*L phosphate‐buffered saline (PBS) buffer (Thermo Fisher Scientific, Hertfordshire, U.K.). Triplet aliquots of 5 *μ*L CE suspension were placed onto polysine‐coated microscope slides (VWR International Ltd, Leicestershire, U.K.). A primary polyclonal antibody (1 : 25; rabbit anti‐human 12R‐LOX, 0.32 mg mL^−1^; Thermo Fisher Scientific; Cat\# PA5‐23608, RRID:AB_2541108) was incubated for 4 h at room temperature followed by washing three times with PBS for 5 min before incubating with the secondary antibody (1 : 100; FITC‐coupled mouse anti‐rabbit IgG, H&L chain; ABCAM PLC, Cambridge, U.K.) for 1 h at room temperature (in the dark). Slides were washed with PBS (three times for 5 min) and mounted with 10 *μ*g mL^−1^ Nile red as a control (Sigma‐Aldrich, Dorset, U.K.) in 75% glycerol solution. An additional staining method was prepared with the same approach for eLOX3 (1 : 25; rabbit anti‐human e‐LOX3, Biorbyt Cat\# orb41336, RRID:AB_10998919) with 1 : 100 secondary antibody FITC‐coupled mouse anti‐rabbit (ABCAM PLC, Cambridge, U.K.).

12‐LOX assay {#ics12532-sec-0014}
------------

The assay was adapted from Singh and colleagues' approach to detect 5‐LOX, 12‐LOX and 15‐LOX activities [27](#ics12532-bib-0027){ref-type="ref"}. Each tape was incubated with 0.1% Tergitol™‐NP40 in 50 mmol L^−1^ Tris (Sigma‐Aldrich) with Pierce™ Protease Inhibitor Tablets (1 per 10 mL; Thermo Fisher Scientific) for 20 min on a shaker with 600 rpm at 4°C. The reaction buffer was composed of 50 mmol L^−1^ Tris, 4 mmol L^−1^ CaCl~2~, 4 mmol L^−1^ EDTA, 0--50 *μ*mol L^−1^ ethyl linoleic acid (Sigma‐Aldrich), 5 *μ*mol L^−1^ ATP (New England Biolabs, Hitchin, U.K.) and 5 *μ*mol L^−1^ 2′,7′‐dichlorodihydrofluorescein diacetate (H~2~DCFDA) (Thermo Fisher Scientific). H~2~DCFDA is non‐fluorogenic agent that is converted in presence of oxidation into the fluorescent 2′,7′‐dichlorofluorescein which is widely used as indicator for reactive oxygen species. Each component was purged with argon before preparing the reaction buffer. This assay was done with a 50 *μ*L sample and purged 150 *μ*L reaction buffer and measured in a Corning^®^ clear flat bottom black 96‐well plate (Sigma‐Aldrich) with an interval of 1 min for 20 min at 37°C with Ex/Em: 495/527 nm in SpectraMax iD3 (Molecular Devices, Wokingham, U.K.). The anti‐12R‐LOX and eLOX3 polyclonal antibodies used in the immunostaining were diluted in purged 0.5% bovine serum albumin (BSA) in reaction buffer as well as 5‐(methylamino)‐2‐(1‐naphthalenyl)‐4‐oxazolecarbonitrile (ML351) (Sigma‐Aldrich) as a blocker for the LOX enzymes. 12R‐LOX activity was expressed as U min^−1^ normalized to the total SC protein on tape strips.

Statistics {#ics12532-sec-0015}
----------

All statistical analysis was performed with [graphpad prism]{.smallcaps} (version 7). The data passed the D\'Agostino & Pearson\'s normality test; therefore, one‐way ANOVA with Sidak--Holm *post‐hoc* test was chosen to determine statistical differences. Results for each set of experiments are shown as the mean ± SD (*n* = 6 or 12) while statistical significance is represented as \**P* ≤ 0.05, \*\**P* ≤ 0.01, or \*\*\**P* ≤ 0.001.

Results {#ics12532-sec-0016}
=======

The principle of this assay is based on the oxidation of the fluorogenic agent (H~2~DCFDA) by the reactive oxygen species created during the LOX reaction. Buffer‐extracted 12R‐LOX activity was determined with ethyl linoleic acid in order to set‐up a Michaelis‐Menten plot to characterize the obtained activity from the second and eighth tapes of PE cheek and PP post‐auricular samples. All four samples reached their *K* ~m~ value at 5.23 ± 0.07 *μ*mol L^−1^; however, *V* ~max~ was distinctive between both anatomical sites and depths (Fig. [1](#ics12532-fig-0001){ref-type="fig"}). The 12R‐LOX activity reached 3x higher *V* ~max~ values in the PP post‐auricular sites at the surface and the deeper SC layer compared to PE cheek samples.

![Determination of Michaelis constant of 12R‐lipoxygenase (12R‐LOX) in photo‐exposed (PE) cheek (tape 2 and 8) and photo‐protected (PP) post‐auricular (tapes 2 and 8) sites using ethyl linoleic acid as the substrate.](ICS-41-274-g001){#ics12532-fig-0001}

Clear individual staining of 12R‐LOX and eLOX3 positive CEs with a higher intensity in the PP post‐auricular samples were immunohistochemically shown (Fig. [2](#ics12532-fig-0002){ref-type="fig"}). Thus, the selected antibodies can be used for the development of the 12R‐LOX enzyme assay.

![12R‐LOX and eLOX3 immunostaining of CEs from the first and ninth tape stripping of PE Cheek and PP post‐auricular sites with Nile red staining to visualize CLE. Scale bar = 100 *μ*m.](ICS-41-274-g002){#ics12532-fig-0002}

The 12R‐LOX antibody was used to demonstrate the concentration‐dependent decrease in the 12R‐LOX activity. While the 1 : 5000 dilution showed a half‐maximal (\*\*\**P* \< 0.001) and the 1 : 500 dilution a full enzyme inhibition (\*\*\**P* \< 0.001), the control (0.5% BSA) did not impact the activity (Fig. [3](#ics12532-fig-0003){ref-type="fig"}). Moreover, the same approach was performed using a LOX inhibitor (ML351) which also did not influence the 12R‐LOX activity (Fig. [4](#ics12532-fig-0004){ref-type="fig"}). A proof of concept experiment was performed with the antibody for eLOX3 that was used in the immunostaining (Fig. [2](#ics12532-fig-0002){ref-type="fig"}) with the same set‐up as for the 12R‐LOX activity assay (Fig. [3](#ics12532-fig-0003){ref-type="fig"}). This assay showed no difference in 12R‐LOX activity in the presence of eLOX3 antibody (Fig. [5](#ics12532-fig-0005){ref-type="fig"}) in contrast to the results obtained in the presence of 12R‐LOX antibody.

![12R‐LOX activity was blocked in PE cheek and PP post‐auricular samples of the second and eighth tape strippings with a polyclonal 12R‐LOX antibody. About 0.5% BSA was used as the control. Data are shown as mean ± SD,*n* = 6 \**P* ≤ 0.05, \*\**P* ≤ 0.01, or \*\*\**P* ≤ 0.0001.](ICS-41-274-g003){#ics12532-fig-0003}

![12R‐LOX activity in PE cheek and PP post‐auricular samples was not affected by the unspecific LOX inhibitor ML351. 1% DMSO was used as the control. Data are shown as mean ± SD,*n* = 6. No significant differences were found.](ICS-41-274-g004){#ics12532-fig-0004}

![12R‐LOX activity was not blocked by the polyclonal eLOX3 antibody. 0.5% BSA was used the control. Data are shown as mean ± SD,*n* = 6. No significant differences were found.](ICS-41-274-g005){#ics12532-fig-0005}

Pearson\'s correlation test was performed between CE rigidity and hydrophobicity as well as RCEM of the first and ninth tape strippings and the obtained 12R‐LOX activity PE cheek and PP post‐auricular samples from the second and eighth tape strippings. This revealed a positive correlation for PE cheek and PP post‐auricular maturation and the enzyme activity of 12R‐LOX (Fig. [6](#ics12532-fig-0006){ref-type="fig"}). The TEWL upon tape stripping can be used to reflect the SC integrity of the PE cheek and PP post‐auricular sites which was correlated to their corresponding 12R‐LOX activity. This demonstrated a clear negative correlation where high TEWL is associated with low 12R‐LOX activity (Fig. [7](#ics12532-fig-0007){ref-type="fig"}).

![Pearson\'s correlation of 12R‐LOX activity and the CE rigidity and hydrophobicity that indicate relative CE maturity (RCEM) were strongly positive in SC surface and deeper SC layers of both anatomical sites.](ICS-41-274-g006){#ics12532-fig-0006}

![Pearson\'s correlation of SC integrity after nine tape strippings and the 12R‐LOX activity in the deeper SC layers (tape 8) show a clear negative relationship.](ICS-41-274-g007){#ics12532-fig-0007}

Discussion {#ics12532-sec-0017}
==========

The importance of essential fatty acid‐containing lipids for skin physiology was highlighted from the early work of Burr & Burr (1930) [28](#ics12532-bib-0028){ref-type="ref"}. Later, it was demonstrated that these benefits were derived from lipoxygenase‐catalysed conversion of linoleoyl‐acyl‐ceramides [29](#ics12532-bib-0029){ref-type="ref"}, [30](#ics12532-bib-0030){ref-type="ref"}. The importance of these metabolic products, their formation and role in CLE formation was highlighted by the work of Brash and collaborators who focused on 12R‐LOX as the first enzyme in ceramide EOS linoleate oxidation [14](#ics12532-bib-0014){ref-type="ref"}, [15](#ics12532-bib-0015){ref-type="ref"}, [16](#ics12532-bib-0016){ref-type="ref"}, [17](#ics12532-bib-0017){ref-type="ref"}. However, we were interested in this enzyme because of the known reduced maturation of facial SC corneocytes [9](#ics12532-bib-0009){ref-type="ref"}, [10](#ics12532-bib-0010){ref-type="ref"}, [31](#ics12532-bib-0031){ref-type="ref"}, [32](#ics12532-bib-0032){ref-type="ref"} as reduced mass levels of 12R‐LOX were recently reported in Caucasian facial SC [21](#ics12532-bib-0021){ref-type="ref"}. This finding was accompanied with lower 12R‐LOX mass levels in Albino Africans compared to Black Africans and Caucasians [33](#ics12532-bib-0033){ref-type="ref"}.

This work is the first measurement of 12R‐LOX activity obtained from facial SC tape strippings based on an assay from a previously published fluorogenic LOX method [27](#ics12532-bib-0027){ref-type="ref"}. This subtype of the LOX enzymes has only recently attracted attention from skin scientists and, therefore, specific substrates and inhibitors are yet not fully commercialized. Ethyl linoleic acid was chosen as the substrate as it resembles the esterified linoleic acid domain in CER EOS which is the natural substrate of 12R‐LOX. The enzyme activity showed the same *K* ~m~ value (5.23 ± 0.07 *μ*mol L^−1^) in all tested samples. Samples from less mature deeper SC layers (tape 8) of both anatomical sites had a higher enzyme activity than those from more mature superficial layers (tape 2); however, samples taken from the PP post‐auricular test site have a higher enzyme activity compared to PE cheek samples. The obtained fluorescence had to be validated to be certain that it originates from 12R‐LOX activity. Direct methods in terms of activation or inhibition are not yet available but antibodies are natural glycoproteins that can detect and bind a specific antigen which was chosen as a suitable blocking agent in this experimental set‐up. The immunostaining showed a clear fluorescence signal on CEs for both, 12R‐LOX and eLOX3, which was proof of antigen detection. A general unspecific LOX inhibitor (ML351) was used to exclude 5‐LOX, 12‐LOX and 15‐LOX activities. The presence of the eLOX3 antibody was ineffective in reducing the detected fluorescence which revealed that the inhibition by 12R‐LOX antibody is not owing to an unspecific spatial blockage by the antibody but an antigen‐specific blocking of 12R‐LOX. A parallel study investigated the impact of 12R‐LOX antibody in *ex vivo* CE maturation showing that CE rigidity improved while CE hydrophobicity remained unchanged in all tested samples (data not shown).The lower 12R‐LOX activity in PE samples is consistent with the reduced 12R‐LOX protein mass levels in PE cheek compared to PP post‐auricular sites [21](#ics12532-bib-0021){ref-type="ref"} as well as reduced CE maturation on this site [9](#ics12532-bib-0009){ref-type="ref"}, [10](#ics12532-bib-0010){ref-type="ref"}, [31](#ics12532-bib-0031){ref-type="ref"}, [32](#ics12532-bib-0032){ref-type="ref"}. Decreased 12R‐LOX activity and reduced corneocyte maturation *ex vivo* demonstrate the importance of this enzyme for the SC maturation by influencing the CE hydrophobicity (D. Guneri, unpublished data). Further work is ongoing to increase epidermal gene expression and enzyme activity of 12R‐LOX in order to enhance CE hydrophobicity thereby contributing to the SC barrier function.

In conclusion, the importance of the hydroxylated variants of linoleoyl ceramide EOS first identified in the late 1980s [30](#ics12532-bib-0030){ref-type="ref"} together with the subsequent cloning and mechanistic studies on 12R‐LOX from in the late 1990s [15](#ics12532-bib-0015){ref-type="ref"} onwards and the reported reduced mass levels of 12R‐LOX in photodamaged facial skin [21](#ics12532-bib-0021){ref-type="ref"} guided our activity‐based studies on 12R‐LOX. We report a novel antibody inhibition fluorescence‐based assay to show depth activity profiles in the SC and reduced activity in photodamaged SC that correlates with poor CE hydrophobicity. This assay will be of use in other disorders of SC maturation.
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